← Back to Analyst Consensus 
PRME Buy
Prime Medicine, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 30, 2026 (4 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 25, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Aug 25, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Aug 19, 2026 | BMO Capital | initiate | Outperform → Outperform | — | 53% |
| Aug 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 29, 2026 | HC Wainwright & Co. | upgrade | Neutral → Buy | — | 44% |
| Mar 12, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Dec 23, 2025 | LifeSci Capital | initiate | — → Outperform | $6 | 57% |
| Nov 11, 2025 | Citigroup | maintain | Neutral → Neutral | $4.25 | 54% |
| Nov 10, 2025 | Chardan Capital | maintain | Buy → Buy | $9 | 47% |
| Aug 12, 2025 | Citigroup | maintain | Neutral → Neutral | $4 | 54% |
| Aug 8, 2025 | Chardan Capital | maintain | Buy → Buy | $10 | 47% |
| May 27, 2025 | Citigroup | downgrade | Buy → Neutral | $1.5 | 54% |
| May 20, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $6 | 53% |
| May 20, 2025 | JP Morgan | downgrade | Overweight → Neutral | $0 | 54% |
| May 20, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| May 19, 2025 | Chardan Capital | maintain | Buy → Buy | $12 | 47% |
| Mar 20, 2025 | Chardan Capital | maintain | Buy → Buy | $16 | 47% |
| Mar 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 4, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $10 | 49% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 3, 2025 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Dec 10, 2024 | JMP Securities | initiate | — → Market Outperform | $10 | 53% |
| Dec 3, 2024 | Guggenheim | reiterate | Buy → Buy | $18 | 52% |
| Oct 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 20, 2024 | HC Wainwright & Co. | initiate | — → Buy | $10 | 44% |
| May 16, 2024 | Citigroup | upgrade | Neutral → Buy | $10 | 54% |
| May 13, 2024 | JP Morgan | maintain | Overweight → Overweight | $15 | 54% |
| Apr 23, 2024 | Wedbush | reiterate | Outperform → Outperform | $12 | 58% |
| Apr 22, 2024 | Chardan Capital | initiate | — → Buy | $17 | 47% |
| Apr 8, 2024 | TD Cowen | initiate | — → Buy | $0 | 54% |
| Apr 3, 2024 | Wedbush | initiate | — → Outperform | $12 | 58% |
| Apr 2, 2024 | Wedbush | initiate | — → Outperform | $12 | 58% |
| Mar 8, 2024 | JP Morgan | maintain | Overweight → Overweight | $16 | 54% |
| Mar 5, 2024 | Guggenheim | maintain | Buy → Buy | $20 | 52% |
| Dec 8, 2023 | Citigroup | initiate | — → Neutral | $10 | 54% |
| Nov 7, 2023 | JP Morgan | maintain | Overweight → Overweight | $26 | 54% |
| Oct 9, 2023 | BMO Capital | initiate | — → Outperform | $19 | 53% |
| Sep 6, 2023 | JonesTrading | initiate | — → Buy | $20 | 75% |
| Aug 14, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $19 | 54% |
| Jul 31, 2023 | Guggenheim | initiate | — → Buy | $24 | 52% |
| Apr 18, 2023 | Stifel | initiate | — → Buy | $18 | 53% |
| Jan 24, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $21 | 54% |
| Nov 14, 2022 | JP Morgan | initiate | — → Overweight | $27 | 54% |
| Nov 14, 2022 | Jefferies | initiate | — → Buy | $25 | 52% |
| Nov 14, 2022 | Morgan Stanley | initiate | — → Equal-Weight | $23 | 54% |
| Nov 14, 2022 | Goldman Sachs | initiate | — → Neutral | $22 | 54% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days